Media stories about Intrexon (NYSE:XON) have been trending somewhat positive on Sunday, Accern reports. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intrexon earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.6422996459046 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- Analysts Alert: Intrexon Corp (XON) – ExpertGazette (expertgazette.com)
- Intentions Seeker Stock: Intrexon Corp (XON) – Emn News (emnnews.com)
- Chesco gene therapy company seeks FDA OK to begin human testing of skin disorder treatment – Philadelphia Business Journal (bizjournals.com)
- -$0.31 Earnings Per Share Expected for Intrexon Corp (XON) This Quarter (americanbankingnews.com)
- Keep Your Active Eyes on Technical Indicators – Intrexon Corporation (XON) – Wall Street Morning (wallstreetmorning.com)
XON has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded Intrexon from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. ValuEngine downgraded Intrexon from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Northland Securities reissued a “buy” rating and set a $21.00 price target on shares of Intrexon in a research report on Friday, November 10th. Stifel Nicolaus upped their target price on Intrexon from $39.00 to $57.00 and gave the company a “buy” rating in a research report on Friday, November 10th. Finally, Bank of America decreased their target price on Intrexon from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $38.50.
Intrexon (NYSE:XON) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.02. The business had revenue of $46.02 million during the quarter, compared to analysts’ expectations of $55.17 million. Intrexon had a negative return on equity of 18.68% and a negative net margin of 66.88%. equities research analysts predict that Intrexon will post -1.06 earnings per share for the current fiscal year.
In related news, CEO Randal J. Kirk purchased 1,000,000 shares of the business’s stock in a transaction that occurred on Friday, January 19th. The stock was acquired at an average cost of $12.50 per share, for a total transaction of $12,500,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 55.10% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://stocknewstimes.com/2018/02/11/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-intrexon-xon-share-price.html.
Intrexon Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.